Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Zai Lab Acquires China Rights to GIST Treatment in $205 Million Deal

publication date: Jun 11, 2019

In a $205 million agreement, Zai Lab, a Shanghai-US biopharma, acquired Greater China rights to ripretinib, a treatment for GIST and other solid tumors developed by Deciphera Pharma of Boston. Ripretinib is an oral investigational KIT and PDGFRα kinase switch control inhibitor. Zai will pay $20 million upfront and be responsible for up to $185 million in potential development and commercial milestones, plus royalties on sales. Deciphera is assessing adding China sites to its ongoing global Phase III trial that compares ripretinib to sunitinib in second-line GIST patients. More details....

Stock Symbols: (NSDQ: ZLAB) (NSDQ: DCPH)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital